ERROR:
subscribe to beauty blog via RSSFor Botox Devotees, A Choice
March 20, 2009 10:56 am
Until now, Botox, the face-freezing, line-diminishing miracle injectable, has been the only thing of its kind available to people seeking a little help slowing the aging process. But this week, a French version of the botulinum toxin type A wrinkle treatment was approved for sale in the U.K. and is making moves across the Channel. Called Azzalure, it has already been given the green light by health authorities in 15 European countries, and depending on FDA approval, should enter the U.S. market later this year under the name Reloxin. The drug was developed by the French pharmaceutical company Ipsen and has been sold for years under a different name, Dysport, as a muscle relaxer for spasms. But seeing as how Allergan, which is responsible for Botox, raked in $1.3 billion in global sales last year and has a near monopoly on the market, according to The Wall Street Journal, it’s not all that shocking that competition has been in the works. Ah, the beauty of free market economics.
tags: Allergan Inc., Azzalure, Botox, Ipsen, Reloxin, Skincare
